REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ending March 31, 2023, along with recent operational highlights. Participants can register for the webcast through the provided links. The company is known for its NAV Technology Platform, which includes over 100 novel AAV vectors and is utilized in developing a variety of therapeutic programs. REGENXBIO aims to achieve its "5x'25" strategy, which targets advancing five AAV therapeutics into pivotal or commercial stages by 2025.
- Company is progressing its '5x'25' strategy, aiming for five AAV therapeutics in pivotal or commercial stages by 2025.
- REGENXBIO's NAV Technology Platform utilizes over 100 novel AAV vectors, facilitating a diverse pipeline of potential treatments.
- None.
ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent operational highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-3-to-discuss-first-quarter-2023-financial-results-and-recent-operational-highlights-301808758.html
SOURCE REGENXBIO Inc.
FAQ
When will REGENXBIO announce its financial results for Q1 2023?
What time is the REGENXBIO conference call scheduled for?
What is the focus of REGENXBIO's NAV Technology Platform?
What is the '5x'25' strategy of REGENXBIO?
